AstraZeneca PLC (OTCMKTS:AZNCF) Sees Significant Growth in Short Interest

Posted by Stephan Jacobs on Nov 27th, 2024

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 147,200 shares, an increase of 248.8% from the October 31st total of 42,200 shares. Based on an average daily volume of 3,800 shares, the short-interest ratio is presently 38.7 days.

Institutional Trading of AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Kennedy Capital Management LLC acquired a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

Shares of OTCMKTS:AZNCF traded down $0.11 during midday trading on Wednesday, hitting $131.36. The company’s stock had a trading volume of 4,487 shares, compared to its average volume of 2,665. The business’s 50 day simple moving average is $144.48 and its 200 day simple moving average is $154.24. AstraZeneca has a 12-month low of $118.16 and a 12-month high of $175.00.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.